Objectives: The anti-IL-6 receptor antibody tocilizumab inhibits signaling of IL-6, a key cytokine in rheumatoid arthritis (RA) pathogenesis. The AMBITION study evaluated tocilizumab monotherapy efficacy and safety vs. methotrexate in patients with active RA, who had not previously failed methotrexate/biologics treatment.
Methods: This 24-week, double-blind, double-dummy, parallel-group study, randomized 673 patients to either tocilizumab 8 mg/kg every 4 weeks, or methotrexate, starting at 7.5 mg/week and titrated to 20 mg/week within 8 weeks, or placebo for 8 weeks followed by tocilizumab 8 mg/kg. The primary endpoint was the proportion of patients achieving American College of Rheumatology (ACR) 20 response at Week 24.
Results: The intent-to-treat analysis demonstrated that tocilizumab was superior to methotrexate treatment with a higher ACR20 response (69.9 vs. 52.5%; P<0.0001), and DAS28<2.6 rate (33.6 vs. 12.1%) at Week 24. Mean high sensitivity C-reactive protein (hsCRP) was within the normal range from Week 12 with tocilizumab, whereas levels remained elevated with methotrexate. The incidence of serious adverse events (AEs) with tocilizumab was 3.8% vs. methotrexate, 2.8% (p=0.50), and of serious infections, 1.4% vs. 0.7%, respectively. There was a higher incidence of reversible grade 3 neutropenia (3.1% vs. 0.4%) and increased total cholesterol ≥240 mg/dL (13.2% vs. 0.4%), and a lower incidence of alanine aminotransferase elevations >3x-<5x upper limit of normal (1.0% vs. 2.5%), respectively.
Conclusion: Tocilizumab monotherapy is superior to methotrexate monotherapy, with rapid improvement in RA signs and symptoms, and a favorable benefit-risk, in patients who have not previously failed methotrexate or biologics treatment.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.